This article was originally published in The Gray Sheet
Firm's IntraStent DoubleStrut biliary endoprosthesis gains 510(k) clearance for treatment of peripheral and non-vascular obstructive disease. The balloon-expandable stent combines "flexibility, lumen coverage and radial strength" without compromising performance, the firm maintains. Available in 16, 26, 36, 56, and 76-mm lengths and diameters expandable from 5-10 mm, the IntraStent DoubleStrut is also being studied in clinical trials for an iliac indication
You may also be interested in...
FDA debars Matthew Hebert, USPlabs co-owner “with primarily responsibilities over product packaging design,” for five years from importing dietary ingredients or other articles of food.
Sanofi’s sales grew strongly in the second quarter, driven by the immunologic Dupixent and its vaccines business, with the company also reporting success in a further potential indication for the product, chronic spontaneous urticaria. The big pharma has raised its EPS guidance for the year.
The UK company has raised its forecasts for 2021 after a better-than-expected Q2, even though Vaxzevria remains a very mixed blessing.